Road toward rapid-molecular point of care test to detect novel SARS-coronavirus 2019 (COVID-19): Review from updated literature

Ahmad, Shkaib; Ali, Nida; Kausar, Meena; Misbah, H.; Wahid, Abdul

doi:10.1016/j.aller.2020.06.001

Cited by 15 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global trends presented in Figure 5 highlight the fast-changing and dynamic global response to the development of diagnostic solutions in response to COVID-19 during March to October 2020. Our analysis of this landscape revealed a precipitous surge in the development of diagnostic solutions during March and April (Rapid Growth Phase), correlating with the high demand for IVDs due to the prevalence of the respiratory disease [ 4 , 6 , 25 , 28 ]. The rate of diagnostic technologies emerging for SARS-CoV-2 during this phase averaged 120 per week across all regions.…”

Section: Resultsmentioning

confidence: 99%

“…The focus on MDx solutions in the first wave of the pandemic is linked to the prevalence of the disease and the urgency of early detection and rapid response. Shortages of PCR consumables [ 14 , 15 , 16 , 17 , 18 ] coupled with laboratory testing capacity issues (i.e., sample processing time) [ 4 , 6 , 25 , 28 ] caused a surge in the technological advancements of a variety of molecular-based techniques including clustered regularly interspaced short palindromic repeats (CRISPR), chemiluminescent assays (CLIA) and lateral flow immunoassay (LFIA) [ 5 , 6 , 14 , 15 , 16 , 17 , 18 , 27 , 68 ]. Furthermore, the availability and distribution of these tests was accelerated by regulatory agencies issuing interim approval mechanisms to address this large-scale public health emergency [ 48 , 70 ].…”

Section: Resultsmentioning

confidence: 99%

“…Growing demand for rapid and easy-to-use diagnostics to facilitate testing outside of laboratory settings [ 6 , 19 , 26 , 27 , 28 ], also resulted in a drive in the development of immunological diagnostics (IDx) that detect the presence of viral surface antigens utilizing an antibody (virus IDx), as these tests produce faster results than MDx ( Figure 1 A) [ 29 , 30 , 31 ]. Immunological tests have also been designed to detect the presence of antibodies (IgG/IgM) to a pathogen (antibody IDx) in the serum and plasma drawn from a blood sample ( Figure 1 B) [ 11 , 20 , 21 , 32 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications

et al. 2021

View full text Add to dashboard Cite

Diagnostic testing remains the backbone of the coronavirus disease 2019 (COVID-19) response, supporting containment efforts to mitigate the outbreak. The severity of this crisis and increasing capacity issues associated with polymerase chain reaction (PCR)-based testing, accelerated the development of diagnostic solutions to meet demands for mass testing. The National Institute for Health Research (NIHR) Innovation Observatory is the national horizon scanning organization in England. Since March, the Innovation Observatory has applied advanced horizon scanning methodologies and tools to compile a diagnostic landscape, based upon data captured for molecular (MDx) and immunological (IDx) based diagnostics (commercialized/in development), for the diagnosis of SARS-CoV-2. In total we identified and tracked 1608 diagnostics, produced by 1045 developers across 54 countries. Our dataset shows the speed and scale in which diagnostics were produced and provides insights into key periods of development and shifts in trends between MDx and IDx solutions as the pandemic progressed. Stakeholders worldwide required timely and detailed intelligence to respond to major challenges, including testing capacity and regulatory issues. Our intelligence assisted UK stakeholders with assessing priorities and mitigation options throughout the pandemic. Here we present the global evolution of diagnostic innovations devised to meet changing needs, their regulation and trends across geographical regions, providing invaluable insights into the complexity of the COVID-19 phenomena.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In contrast, microfluidics and biosensor based POC diagnostic are still under development, facing challenges in terms of both implementation and interpretation along with clinical validations. In this era of pandemics, POCT devices will significantly contribute towards economics due to robust and low-cost diagnosis ( Ahmad et al, 2020 ). POC biosensors are portable devices hence can be available in remote locations and resource-limited settings.…”

Section: Commercial Challengesmentioning

confidence: 99%

Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases

Jain

Nehra

Kumar

et al. 2021

Biosensors and Bioelectronics

233

155

View full text Add to dashboard Cite

On global scale, the current situation of pandemic is symptomatic of increased incidences of contagious diseases caused by pathogens. The faster spread of these diseases, in a moderately short timeframe, is threatening the overall population wellbeing and conceivably the economy. The inadequacy of conventional diagnostic tools in terms of time consuming and complex laboratory-based diagnosis process is a major challenge to medical care. In present era, the development of point-of-care testing (POCT) is in demand for fast detection of infectious diseases along with “on-site” results that are helpful in timely and early action for better treatment. In addition, POCT devices also play a crucial role in preventing the transmission of infectious diseases by offering real-time testing and lab quality microbial diagnosis within minutes. Timely diagnosis and further treatment optimization facilitate the containment of outbreaks of infectious diseases. Presently, efforts are being made to support such POCT by the technological development in the field of internet of medical things (IoMT). The IoMT offers wireless-based operation and connectivity of POCT devices with health expert and medical centre. In this review, the recently developed POC diagnostics integrated or future possibilities of integration with IoMT are discussed with focus on emerging and re-emerging infectious diseases like malaria, dengue fever, influenza A (H1N1), human papilloma virus (HPV), Ebola virus disease (EVD), Zika virus (ZIKV), and coronavirus (COVID-19). The IoMT-assisted POCT systems are capable enough to fill the gap between bioinformatics generation, big rapid analytics, and clinical validation. An optimized IoMT-assisted POCT will be useful in understanding the diseases progression, treatment decision, and evaluation of efficacy of prescribed therapy.

show abstract

“…Currently, the most common techniques involve reverse transcriptase PCR (RT-PCR), but many recent POC approaches involve using loop-mediated isothermal amplification (LAMP). LAMP is attractive because of its sensitivity and short run time and because it does not require a thermocycler [ 2 ]. Other nucleic acid-based tests, such as those involving digital droplet PCR and nanoparticle-based DNA amplification, are also being examined because of their superior limit of detection (LOD), sensitivity, and specificity.…”

mentioning

confidence: 99%